ADIL
Adial Pharmaceuticals, Inc.
Price Chart
Latest Quote
$0.21
Current Price| Previous Close | $0.21 |
| Open | $0.21 |
| Day High | $0.22 |
| Day Low | $0.21 |
| Volume | 125,813 |
Stock Information
| Shares Outstanding | 27.78M |
| Cash Equivalents | $4.61M |
| Net Income | $-8.05M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $5.96M |
| EPS (TTM) | $-0.60 |
| Exchange | NCM |
đ Custom Metrics & Score
Score: 14/42| Debt to Equity | 0.24 |
| Debt to Earnings | -0.07 |
| Current Ratio | 4.16 |
| Quick Ratio | 3.84 |
| Return on Equity | -324.41% |
| Avg FCF Growth | -10.60% |
| FCF Yield | -116.06% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $0.21 | 125,813 |
| 2026-01-30 | $0.21 | 258,700 |
| 2026-01-29 | $0.21 | 208,500 |
| 2026-01-28 | $0.22 | 210,900 |
| 2026-01-27 | $0.23 | 208,100 |
| 2026-01-26 | $0.23 | 330,600 |
| 2026-01-23 | $0.23 | 370,100 |
| 2026-01-22 | $0.23 | 215,300 |
| 2026-01-21 | $0.22 | 198,900 |
| 2026-01-20 | $0.22 | 535,200 |
| 2026-01-16 | $0.23 | 256,400 |
| 2026-01-15 | $0.23 | 275,900 |
| 2026-01-14 | $0.22 | 410,800 |
| 2026-01-13 | $0.23 | 249,200 |
| 2026-01-12 | $0.23 | 275,200 |
| 2026-01-09 | $0.24 | 258,300 |
| 2026-01-08 | $0.23 | 274,700 |
| 2026-01-07 | $0.24 | 548,800 |
| 2026-01-06 | $0.25 | 405,100 |
| 2026-01-05 | $0.26 | 537,100 |
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia.
đ° Latest News
Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?
Zacks âĸ 2026-01-06T14:40:03Z
CoreWeave initiated, Instacart downgraded: Wall Street's top analyst calls
The Fly âĸ 2025-09-30T13:42:24Z
Adial Pharmaceuticals Highlights Favorable Comments From FDA Meeting For Lead Program In Alcohol Use Disorder
Benzinga âĸ 2025-09-16T12:03:43Z
All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy
Zacks âĸ 2025-09-01T16:00:02Z
Thermo Fisher Scientific (TMO) Inks Deal to Manufacture Adial Pharmaceuticals ADO4
Insider Monkey âĸ 2025-07-15T13:10:38Z
Adial Pharmaceuticals (ADIL) Upgraded to Strong Buy: Here's Why
Zacks âĸ 2025-07-10T16:00:03Z
Top Midday Decliners
MT Newswires âĸ 2025-06-17T18:50:19ZEXCLUSIVE: Adial Pharmaceuticals Lead Candidate For Alcohol Use Disorder Advances Toward Phase 3 Trial
Benzinga âĸ 2025-06-11T11:30:44Z
EXCLUSIVE: Adial Pharmaceuticals Secures FDA End of Phase 2 Meeting Request To Discuss Upcoming Clinical Development Plan For Lead Program
Benzinga âĸ 2025-05-08T12:02:08Z
EXCLUSIVE: Adial Pharmaceuticals Expands Patent Portfolio With New US Patent For Lead Drug For Alcohol And Opioid Use Disorders
Benzinga âĸ 2025-05-01T12:02:41Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Expenses | $8,284,457 | $6,887,947 | $10,859,475 | $17,740,326 |
| Other Income Expense | $-5,091,653 | $-183,722 | $522,000 | $-1,783,616 |
| Other Non Operating Income Expenses | $-75,043 | $10,162 | - | $46,494 |
| Net Non Operating Interest Income Expense | $178,659 | $69,779 | $63,338 | $6,539 |
| Operating Expense | $8,284,457 | $6,887,947 | $10,859,475 | $17,740,326 |
| General And Administrative Expense | $5,055,231 | $5,620,870 | $8,909,167 | $9,344,678 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-13,197,451 | $-7,001,890 | $-10,796,137 | $-19,423,326 |
| Net Interest Income | $178,659 | $69,779 | $63,338 | $6,539 |
| Interest Income | $178,659 | $69,779 | $63,338 | $6,539 |
| Normalized Income | $-8,733,024 | $-7,001,890 | $-10,796,137 | $-17,602,001 |
| Net Income From Continuing And Discontinued Operation | $-13,197,451 | $-5,123,341 | $-12,731,416 | $-19,423,326 |
| Total Operating Income As Reported | $-8,284,457 | $-6,887,947 | $-10,859,475 | $-19,288,723 |
| Net Income Common Stockholders | $-13,197,451 | $-5,123,341 | $-12,731,416 | $-19,423,326 |
| Net Income | $-13,197,451 | $-5,123,341 | $-12,731,416 | $-19,423,326 |
| Net Income Including Noncontrolling Interests | $-13,197,451 | $-5,123,341 | $-12,731,416 | $-19,423,326 |
| Net Income Discontinuous Operations | $0 | $1,878,549 | $-1,935,279 | - |
| Net Income Continuous Operations | $-13,197,451 | $-7,001,890 | $-10,796,137 | $-19,423,326 |
| Pretax Income | $-13,197,451 | $-7,001,890 | $-10,796,137 | $-19,517,403 |
| Special Income Charges | $-4,464,427 | $0 | $522,000 | $-1,830,110 |
| Earnings From Equity Interest | $-552,183 | $-193,884 | $0 | - |
| Interest Income Non Operating | $178,659 | $69,779 | $63,338 | $6,539 |
| Operating Income | $-8,284,457 | $-6,887,947 | $-10,859,475 | $-17,740,326 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-2.72 | $-3.60 | $-12.71 | $-26.00 |
| Basic EPS | $-2.72 | $-3.60 | $-12.71 | $-26.00 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $-8,785 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-3,819,465 | $-6,887,383 | $-10,858,911 | $-15,855,110 |
| Total Unusual Items | $-4,464,427 | $0 | $522,000 | $-1,830,110 |
| Total Unusual Items Excluding Goodwill | $-4,464,427 | $0 | $522,000 | $-1,830,110 |
| Reconciled Depreciation | $565 | $564 | $564 | $55,106 |
| EBITDA (Bullshit earnings) | $-8,283,892 | $-6,887,383 | $-10,858,911 | $-17,685,220 |
| EBIT | $-8,284,457 | $-6,887,947 | $-10,859,475 | $-17,740,326 |
| Diluted Average Shares | $4,851,487 | $1,424,661 | $1,001,505 | $743,549 |
| Basic Average Shares | $4,851,487 | $1,424,661 | $1,001,505 | $743,549 |
| Diluted NI Availto Com Stockholders | $-13,197,451 | $-5,123,341 | $-12,731,416 | $-19,423,326 |
| Tax Provision | $0 | $0 | $0 | $-94,077 |
| Other Special Charges | $4,464,427 | - | - | - |
| Research And Development | $3,229,226 | $1,267,077 | $1,950,308 | $8,395,648 |
| Selling General And Administration | $5,055,231 | $5,620,870 | $8,909,167 | $9,344,678 |
| Other Gand A | $5,055,231 | $5,620,870 | $8,909,167 | $9,344,678 |
| Write Off | - | - | $0 | $1,548,397 |
| Restructuring And Mergern Acquisition | - | - | $-522,000 | $281,713 |
| Impairment Of Capital Assets | - | - | - | $1,548,397 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $4,064,736 | $4,079,616 | $3,272,017 | $2,798,799 |
| Total Assets | $5,043,942 | $4,736,605 | $5,732,804 | $7,474,975 |
| Total Non Current Assets | $985,178 | $1,537,926 | $952,869 | $1,013,370 |
| Goodwill And Other Intangible Assets | $3,348 | $3,913 | $4,477 | $709,012 |
| Current Assets | $4,058,764 | $3,198,679 | $4,779,935 | $6,461,605 |
| Other Current Assets | $308,239 | $371,597 | $349,441 | $389,501 |
| Cash Cash Equivalents And Short Term Investments | $3,750,525 | $2,827,082 | $4,001,794 | $6,062,173 |
| Cash And Cash Equivalents | $3,750,525 | $2,827,082 | $4,001,794 | $6,062,173 |
| Other Intangible Assets | - | $3,913 | $4,477 | $460,041 |
| Assets Held For Sale Current | - | $0 | $428,700 | - |
| Other Non Current Assets | - | - | $948,392 | - |
| Prepaid Assets | - | - | $428,700 | $9,931 |
| Non Current Prepaid Assets | - | - | - | $0 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | - | - | $207,375 | $256,960 |
| Long Term Debt And Capital Lease Obligation | - | - | $150,547 | $207,375 |
| Current Debt And Capital Lease Obligation | - | - | $56,828 | $49,585 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $975,858 | $653,076 | $2,456,310 | $3,967,164 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $665,444 | $1,244,774 |
| Current Liabilities | $975,858 | $653,076 | $1,790,866 | $2,722,390 |
| Payables And Accrued Expenses | $570,612 | $231,711 | $653,228 | $2,142,327 |
| Payables | $298,402 | $127,387 | $276,410 | $286,192 |
| Accounts Payable | $250,130 | $103,325 | $276,410 | $286,192 |
| Liabilities Heldfor Sale Non Current | - | $0 | $665,444 | - |
| Other Non Current Liabilities | - | - | $492,000 | $1,014,000 |
| Non Current Deferred Liabilities | - | - | $22,897 | $23,399 |
| Non Current Deferred Taxes Liabilities | - | - | $22,897 | $23,399 |
| Other Current Liabilities | - | - | $376,129 | $9,683 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $4,068,084 | $4,083,529 | $3,276,494 | $3,507,811 |
| Total Equity Gross Minority Interest | $4,068,084 | $4,083,529 | $3,276,494 | $3,507,811 |
| Stockholders Equity | $4,068,084 | $4,083,529 | $3,276,494 | $3,507,811 |
| Retained Earnings | $-81,995,323 | $-68,797,872 | $-63,674,531 | $-50,943,115 |
| Long Term Equity Investment | $981,830 | $1,534,013 | $0 | - |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $6,474,588 | $1,663,421 | $1,067,491 | $837,868 |
| Share Issued | $6,474,588 | $1,663,421 | $1,067,491 | $837,868 |
| Tangible Book Value | $4,064,736 | $4,079,616 | $3,272,017 | $2,798,799 |
| Invested Capital | $4,068,084 | $4,083,529 | $3,276,494 | $3,507,811 |
| Working Capital | $3,082,906 | $2,545,603 | $2,989,069 | $3,739,215 |
| Total Capitalization | $4,068,084 | $4,083,529 | $3,276,494 | $3,507,811 |
| Additional Paid In Capital | $86,056,934 | $72,879,738 | $66,949,958 | $54,429,979 |
| Capital Stock | $6,473 | $1,663 | $1,067 | $20,947 |
| Common Stock | $6,473 | $1,663 | $1,067 | $20,947 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $405,246 | $421,365 | $761,509 | $520,795 |
| Current Accrued Expenses | $272,210 | $104,324 | $376,818 | $1,856,135 |
| Dueto Related Parties Current | $48,272 | $24,062 | $0 | - |
| Investments And Advances | $981,830 | $1,534,013 | $0 | - |
| Treasury Shares Number | - | $0 | - | - |
| Capital Lease Obligations | - | - | $207,375 | $256,960 |
| Long Term Capital Lease Obligation | - | - | $150,547 | $207,375 |
| Current Capital Lease Obligation | - | - | $56,828 | $49,585 |
| Goodwill | - | - | $248,971 | $248,971 |
| Net PPE | - | - | $244,421 | $304,358 |
| Gross PPE | - | - | $244,421 | $304,358 |
| Other Properties | - | - | $50,424 | $58,149 |
| Buildings And Improvements | - | - | $193,997 | $246,209 |
| Properties | - | - | $0 | $0 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-6,922,306 | $-6,806,809 | $-11,185,985 | $-12,014,034 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-6,922,306 | $-6,806,809 | $-11,185,985 | $-11,949,429 |
| Cash Flow From Continuing Operating Activities | $-6,922,306 | $-5,803,368 | $-8,593,866 | $-11,949,429 |
| Operating Gains Losses | $552,183 | $193,884 | - | $-22,134 |
| Cash From Discontinued Operating Activities | - | $-1,003,441 | $-2,592,119 | - |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Investing Cash Flow | $0 | $1,500,000 | $0 | $-34,016 |
| Cash Flow From Continuing Investing Activities | $0 | $1,500,000 | $0 | $-34,016 |
| Net Other Investing Changes | - | $1,500,000 | - | - |
| Capital Expenditure | - | - | - | $-64,605 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $4,021,485 | $749,943 | $9,123,741 | $11,750,005 |
| Financing Cash Flow | $7,845,749 | $4,132,097 | $9,125,606 | $13,644,504 |
| Cash Flow From Continuing Financing Activities | $7,845,749 | $4,132,097 | $9,125,606 | $13,644,504 |
| Net Common Stock Issuance | $4,021,485 | $749,943 | $9,123,741 | $11,750,005 |
| Common Stock Issuance | $4,021,485 | $749,943 | $9,123,741 | $11,750,005 |
| Net Other Financing Charges | - | $-1,661 | - | - |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Paid Supplemental Data | $0 | $0 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $3,750,525 | $2,827,082 | $4,001,794 | $6,062,173 |
| Beginning Cash Position | $2,827,082 | $4,001,794 | $6,062,173 | $4,401,114 |
| Changes In Cash | $923,443 | $-1,174,712 | $-2,060,379 | $1,661,059 |
| Proceeds From Stock Option Exercised | $3,824,264 | $3,383,815 | $1,865 | $1,894,499 |
| Change In Working Capital | $386,140 | $-794,205 | $-1,172,786 | $1,464,475 |
| Change In Payables And Accrued Expense | $322,782 | $-772,049 | $-1,222,777 | $1,166,520 |
| Change In Accrued Expense | $151,767 | $-612,638 | $-1,238,603 | $1,520,291 |
| Change In Payable | $171,015 | $-159,411 | $15,826 | $-353,771 |
| Change In Account Payable | $171,015 | $-159,411 | $15,826 | $-353,771 |
| Change In Prepaid Assets | $63,358 | $-22,156 | $49,991 | $335,292 |
| Other Non Cash Items | $4,539,426 | $51,901 | $-522,000 | $281,713 |
| Stock Based Compensation | $796,831 | $1,746,378 | $3,374,493 | $4,240,417 |
| Depreciation Amortization Depletion | $565 | $564 | $564 | $55,106 |
| Depreciation And Amortization | $565 | $564 | $564 | $55,106 |
| Amortization Cash Flow | $565 | $564 | $564 | $565 |
| Amortization Of Intangibles | $565 | $564 | $564 | $565 |
| Earnings Losses From Equity Investments | $552,183 | $193,884 | $0 | - |
| Net Income From Continuing Operations | $-13,197,451 | $-7,001,890 | $-10,796,137 | $-19,423,326 |
| Net Business Purchase And Sale | - | - | $0 | $30,589 |
| Sale Of Business | - | - | $0 | $30,589 |
| Net PPE Purchase And Sale | - | - | $0 | $-64,605 |
| Purchase Of PPE | - | - | $0 | $-64,605 |
| Change In Other Current Liabilities | - | - | $-49,585 | $-37,337 |
| Asset Impairment Charge | - | - | $0 | $1,548,397 |
| Deferred Tax | - | - | $-502 | $-94,077 |
| Deferred Income Tax | - | - | $-502 | $-94,077 |
| Depreciation | - | - | $59,937 | $54,541 |
| Gain Loss On Sale Of PPE | - | - | $0 | $6,954 |